Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

UTHR stock hub

United Therapeutics Corporation has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

UTHRis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

24B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

UTHR

In the news

Latest news · UTHR

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E19.8

P25 12.3P50 18.4P75 33.1

Trailing P/E20.9

P25 14.9P50 23.2P75 38.5

ROE20.3

P25 -105.6P50 -46.5P75 -3.1

ROIC29.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All UTHR market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

259

Groups with data

Currency

USD

Showing 259 of 259 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001082554
Company name	United Therapeutics Corporation
Country	United States
Country code	US
Cusip	91307C102
Employees	1,400
Employees Change	95%
Employees Change Percent	7.28
Enterprise value	$20.5B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	1999-06-17
Isin	US91307C1027
Last refreshed	2026-05-10
Market cap	$24B
Market cap category	Large-Cap
Price	$565
Price currency	USD
Rev Per Employee	2,264,142.86x
Sector	Healthcare
Sic	2834
Symbol	UTHR
Website	https://www.unither.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.37%
EV Earnings	15.93x
EV Sales Forward	6.07x
EV/EBIT	14.05x
EV/EBITDA	13.24x
EV/FCF	20.17x
EV/Sales	6.47x
FCF yield	4.24%
Forward P/E	19.76x
P/B ratio	4.04x
P/E ratio	20.87x
P/S ratio	7.57x
PE Ratio10 Y	12.6x
PE Ratio3 Y	13.16x
PE Ratio5 Y	14.36x
PEG ratio	2.03x
PS Forward	7.1x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	46.06%
EBITDA Margin	48.85%
FCF margin	32.08%
Gross margin	86.58%
Gross Profit	$2.7B
Gross Profit Growth	2.99%
Gross Profit Growth Q	-7.66%
Gross Profit Growth3 Y	15.03%
Gross Profit Growth5 Y	14.44%
Net Income	$1.3B
Net Income Growth	6.34%
Net Income Growth Q	-14.68%
Net Income Growth Years	4%
Net Income Growth3 Y	20.91%
Net Income Growth5 Y	26%
Pretax Margin	50.75%
Profit Margin	40.61%
Profit Per Employee	$919,571
Profitable Years	6
ROA	12.62
Roa5y	11.19
ROCE	23.88
ROE	20.26
Roe5y	17.35
ROIC	29.36
Roic5y	27.77

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	17.98%
Cagr15y	15.4%
Cagr1y	84.15%
Cagr20y	16.19%
Cagr3y	38.17%
Cagr5y	23.66%
EPS Growth	7.82
EPS Growth Q	-12.22
EPS Growth Years	4
EPS Growth3 Y	22.08
EPS Growth5 Y	24.71
FCF Growth	-9.9%
FCF Growth Q	-6.16%
FCF Growth3 Y	12.09%
FCF Growth5 Y	12.12%
OCF Growth	10.73%
OCF Growth Q	0.46%
OCF Growth10 Y	14.62%
OCF Growth3 Y	20.72%
OCF Growth5 Y	19.9%
Revenue Growth	5.87x
Revenue Growth Q	-1.62x
Revenue Growth Years	6x
Revenue Growth3 Y	16.96x
Revenue Growth5 Y	16.05x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.44
Assets	$6.7B
Cash	$2.2B
Current Assets	$2.9B
Current Liabilities	$599.1M
Equity	$5.9B
Interest Coverage	89.03
Liabilities	$813.1M
Long Term Assets	$3.8B
Long Term Liabilities	$214M
Net Cash	$3.5B
Net Cash By Market Cap	$14.48
Net Cash Growth	-28.16%
Net Debt EBITDA	$-2.24
Net Debt Equity	$-0.59
Net Debt FCF	$-3.41
Tangible Book Value	$5.8B
Tangible Book Value Per Share	$137
WACC	7.52

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.79
Inventory Turnover	2.47
Net Working Capital	$119.2M
Quick ratio	4.12
Working Capital	$2.3B
Working Capital Turnover	$1.15

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.4%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	422.32%
1Y total return	84.07%
200-day SMA	462.3
3Y total return	163.84%
50-day SMA	552.4
50-day SMA vs 200-day SMA	50over200
5Y total return	189.09%
All Time High	609.4
All Time High Change	-7.29%
All Time High Date	2026-05-06
All Time Low	4.28
All Time Low Change	13,114.97%
All Time Low Date	2001-12-11
ATR	17.24
Beta	0.6
Beta1y	0.4
Beta2y	0.55
Ch YTD	15.95
High	573.5
High52	609.4
High52 Date	2026-05-06
High52ch	-7.29%
Low	561.2
Low52	272.1
Low52 Date	2025-07-31
Low52ch	107.61%
Ma50ch	2.26%
Price vs 200-day SMA	22.21%
RSI	48.81
RSI Monthly	73.94
RSI Weekly	65.62
Sharpe ratio	1.38x
Sortino ratio	3.18
Total Return	1.4%
Tr YTD	15.95
Tr15y	757.14%
Tr1m	-0.13%
Tr1w	-0.96%
Tr3m	16.4%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	14
Analyst Count Top	7
Analyst Price Target Top	$549
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$6.83
Earnings EPS Estimate Growth	3.02
Earnings Revenue Estimate	797,970,872x
Earnings Revenue Estimate Growth	0.45x
Operating Income	$1.5B
Operating Income Growth	-1.21
Operating Income Growth Q	-14.89
Operating Income Growth3 Y	14
Operating Income Growth5 Y	23.95
Operating margin	46.06
Price target	$583
Price Target Change	$3.26
Price Target Change Top	$-2.8

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	38,936,272%
Float Percent	91.73%
Net Borrowing	-200,000,000
Shares Insiders	1.98%
Shares Institutions	94.37%
Shares Out	42,446,733
Shares Qo Q	-0.21%
Shares Yo Y	-1.4%
Short Float	6.94%
Short Ratio	4.23
Short Shares	6.37

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$867.1M
Average Volume	426,497.75x
Bv Per Share	140
CAPEX	$-546.4M
Ch10y	422.3
Ch15y	757.1
Ch1m	-0.13
Ch1w	-0.96
Ch1y	84.07
Ch20y	1,912.3
Ch3m	16.4
Ch3y	163.8
Ch5y	189.1
Ch6m	25.85
Change	-0.74%
Change From Open	-0.74
Close	569.2
Days Gap	0
Depreciation Amortization	88,400,000
Dollar Volume	355,057,445.8
Earnings Date	2026-05-06
Earnings Time	bmo
EBIT	$1.5B
EBITDA	$1.5B
EPS	$27.07
F Score	5
FCF	$1B
FCF EV Yield	4.96x
FCF Per Share	$23.96
Financing CF	-2,540,600,000
Fiscal Year End	December
Founded	1,996
Graham Number	291.96953
Graham Upside	-48.32
Income Tax	$321.3M
Investing CF	357,100,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Date	2009-09-23
Last Split Type	Forward
Last10k Filing Date	2026-02-25
Lynch Fair Value	$677
Lynch Upside	19.77
Ma150	498.6
Ma150ch	13.31%
Ma20	574.9
Ma20ch	-1.72%
Net CF	-620,200,000
Next Earnings Date	2026-07-29
Open	569.2
Optionable	Yes
P FCF Ratio	23.58
P OCF Ratio	15.34
Position In Range	30.36
Ppne	1,840,700,000
Price Date	2026-05-08
Price EBITDA	$15.49
Ptbv Ratio	4.14
Relative Volume	1.47x
Revenue	3,169,800,000x
SBC By Revenue	4.73x
Share Based Comp	149,800,000
Tax By Revenue	10.14x
Tax Rate	19.97%
Tr20y	1,912.25%
Tr6m	25.85%
Us State	Maryland
Volume	628,487
Z Score	16.45

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does UTHR pay a dividend?

Capital-return profile for this ticker.

Performance

UTHR stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns UTHR?

Insider, institutional, and short-interest positioning.

Institutional ownership

+94.4%

Float: +91.7% of shares outstanding

Insider ownership

+2.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

UTHR momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

48.8

Neutral momentum band

Price vs 200-day MA

+22.2%

50/200-day relationship not available

Beta (5Y)

0.60

Less volatile than the market

Sharpe ratio

1.38

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About UTHR

Hub-level FAQ points readers to the deeper analysis pages.

What is the current UTHR stock rating?

United Therapeutics Corporation is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full UTHR analysis?

The full report lives at /stocks/UTHR/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for UTHR?

The latest report frames UTHR around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the UTHR page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.